Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Public ClinicalTrials.gov record NCT01193842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy alone in treating patients with human immunodeficiency virus-related diffuse large B-cell non-Hodgkin lymphoma or other aggressive B-cell lymphomas. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving vorinostat together with combination chemotherapy and rituximab may kill more cancer cells.
Study identification
- NCT ID
- NCT01193842
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 107 participants
Conditions and interventions
Conditions
- AIDS-Related Plasmablastic Lymphoma
- AIDS-Related Primary Effusion Lymphoma
- Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage I Grade 3 Follicular Lymphoma
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage III Grade 3 Follicular Lymphoma
- Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage IV Grade 3 Follicular Lymphoma
- HIV Infection
- Plasmablastic Lymphoma
- Primary Effusion Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
Interventions
- Cyclophosphamide Drug
- Doxorubicin Hydrochloride Drug
- Etoposide Drug
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Prednisone Drug
- Rituximab Biological
- Vincristine Sulfate Drug
- Vorinostat Drug
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2010 (Actual)
- Primary completion
- Nov 12, 2016 (Actual)
- Completion
- May 19, 2022 (Actual)
- Last update posted
- Nov 21, 2023
2010 – 2022
United States locations
- U.S. sites
- 35
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jackson Hospital and Clinic | Montgomery | Alabama | 36106 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UCLA Center for Clinical AIDS Research and Education | Los Angeles | California | 90035 | — |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
| San Diego VA Medical Center | San Diego | California | 92161 | — |
| Zuckerberg San Francisco General Hospital | San Francisco | California | 94110 | — |
| UCSF Medical Center-Parnassus | San Francisco | California | 94143 | — |
| Jackson Memorial Hospital-Holtz Children's Hospital | Miami | Florida | 33136 | — |
| University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida | 33136 | — |
| UM Sylvester Comprehensive Cancer Center at Kendall | Miami | Florida | 33176 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| John H Stroger Jr Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Stroger Hospital of Cook County MBCCOP | Chicago | Illinois | 60612 | — |
| Louisiana State University Health Science Center | New Orleans | Louisiana | 70112 | — |
| University Medical Center New Orleans | New Orleans | Louisiana | 70112 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | — |
| Washington University - Jewish | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Montefiore Medical Center-Einstein Campus | The Bronx | New York | 10461 | — |
| Montefiore Medical Center-Weiler Hospital | The Bronx | New York | 10461 | — |
| Montefiore Medical Center - Moses Campus | The Bronx | New York | 10467 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Pennsylvania Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Miriam Hospital | Providence | Rhode Island | 02906 | — |
| Thomas Street Clinic | Houston | Texas | 77009 | — |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | Texas | 77030 | — |
| Ben Taub General Hospital | Houston | Texas | 77030 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Harborview Medical Center | Seattle | Washington | 98104 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01193842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2023 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01193842 live on ClinicalTrials.gov.